# Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML

> **NCT04365179** · PHASE1 · RECRUITING · sponsor: **Immune System Key Ltd** · enrollment: 18 (estimated)

## Conditions studied

- Advanced MDS
- AML

## Interventions

- **DRUG:** Nerofe

## Key facts

- **NCT ID:** NCT04365179
- **Lead sponsor:** Immune System Key Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-06-18
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-08-30
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2024-07-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04365179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04365179, "Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04365179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*